COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

COLO.B.DK

629.8

+0.41%↑

GMAB.DK

1,447

+0.87%↑

ZEAL.DK

476.3

+2.32%↑

AMBUB.DK

99.45

+0.1%↑

Search

Novo Nordisk A-S (Class B)

Fechado

490.95 3.11

Visão Geral

Variação de preço das ações

24h

Atual

Mín

485.05

Máximo

492.1

Indicadores-chave

By Trading Economics

Rendimento

804M

29B

Vendas

-7.6B

78B

P/E

Médio do Setor

20.239

51.198

EPS

6.53

Rendimento de Dividendos

3.33

Margem de lucro

37.182

Funcionários

77,406

EBITDA

4.1B

39B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+9.53% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.33%

2.40%

Próximos Ganhos

6 de ago. de 2025

Próxima data de dividendos

18 de ago. de 2025

Próxima data de ex-dividendo

14 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-8B

2T

Abertura anterior

487.84

Fecho anterior

490.95

Novo Nordisk A-S (Class B) Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de mai. de 2025, 11:36 UTC

Principais Notícias

Novo Nordisk CEO to Step Down Amid Market Challenges

12 de mai. de 2025, 09:36 UTC

Grandes Movimentos do Mercado

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

7 de mai. de 2025, 11:29 UTC

Principais Notícias
Ganhos
Grandes Movimentos do Mercado

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

7 de mai. de 2025, 07:05 UTC

Ganhos

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales -- Update

7 de mai. de 2025, 06:19 UTC

Ganhos

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales

3 de jun. de 2025, 15:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

29 de mai. de 2025, 01:00 UTC

Principais Notícias

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

20 de mai. de 2025, 14:08 UTC

Ganhos

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

20 de mai. de 2025, 07:43 UTC

Conversa de Mercado

Novo Nordisk Guidance at Risk After CEO News -- Market Talk

16 de mai. de 2025, 18:35 UTC

Principais Notícias

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 de mai. de 2025, 17:34 UTC

Principais Notícias

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 2nd Update

16 de mai. de 2025, 13:42 UTC

Ações em Alta

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16 de mai. de 2025, 13:27 UTC

Conversa de Mercado

Novo Nordisk CEO Departure Comes as a Surprise -- Market Talk

16 de mai. de 2025, 13:15 UTC

Principais Notícias

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- Update

16 de mai. de 2025, 12:17 UTC

Ganhos

Novo Nordisk Chairman: No Link Between CEO Change and Other Recent Exec Departures

12 de mai. de 2025, 22:14 UTC

Principais Notícias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 de mai. de 2025, 18:45 UTC

Principais Notícias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 de mai. de 2025, 12:07 UTC

Conversa de Mercado

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 de mai. de 2025, 07:20 UTC

Conversa de Mercado

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

7 de mai. de 2025, 15:13 UTC

Ganhos

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

7 de mai. de 2025, 13:56 UTC

Ganhos

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 de mai. de 2025, 13:45 UTC

Ganhos

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

7 de mai. de 2025, 11:25 UTC

Ganhos

These Stocks Are Moving the Most Today: Super Micro, AMD, Disney, Uber, Novo Nordisk, Sarepta, EA, Tesla, and More -- Barrons.com

7 de mai. de 2025, 11:18 UTC

Ganhos

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7 de mai. de 2025, 09:55 UTC

Ganhos

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Disney, and More -- Barrons.com

7 de mai. de 2025, 09:36 UTC

Ganhos

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Tesla, and More -- Barrons.com

7 de mai. de 2025, 09:04 UTC

Ganhos
Ações em Alta

Stocks to Watch Wednesday: Disney, Uber, Super Micro -- WSJ

7 de mai. de 2025, 08:10 UTC

Conversa de Mercado

Novo Nordisk Cuts Guidance Slightly More Than Expected -- Market Talk

7 de mai. de 2025, 08:08 UTC

Conversa de Mercado

Novo Nordisk's Downgraded Guidance Assumes Large Wegovy Uplift in 2H -- Market Talk

7 de mai. de 2025, 07:11 UTC

Conversa de Mercado
Ganhos

Novo Nordisk Shares Seen Under Pressure After Downgrade -- Market Talk

Comparação entre Pares

Variação de preço

Novo Nordisk A-S (Class B) Previsão

Preço-alvo

By TipRanks

9.53% parte superior

Previsão para 12 meses

Média 1,162.73 DKK  9.53%

Máximo 1,550 DKK

Mínimo 720 DKK

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Novo Nordisk A-S (Class B) - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

7

Comprar

2

Manter

2

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.